Metraipolis › archive › dc_76cbdae4a63f

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies — Europe PMC PMID:41225624

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41225624
DOI
10.1186/s13045-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-08T15:09:49.787Z
SHA-256 of the archived text
e117e0db7a975d5cda8cc254ba4716ae3c76dad4a196021c85c38652c150c8ad
Stable URL of this page
https://metraipolis.com/documento/dc_76cbdae4a63f

How to cite

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies — Europe PMC PMID:41225624 — Europe PMC (en), https://europepmc.org/article/MED/41225624 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_76cbdae4a63f (Metraipolis archive dc_76cbdae4a63f, sha256 e117e0db7a975d5cda8cc254ba4716ae3c76dad4a196021c85c38652c150c8ad)
BibTeX
@misc{dc76cbdae4a63f,
  title = {First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies — Europe PMC PMID:41225624},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41225624},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_76cbdae4a63f; sha256 e117e0db7a975d5cda8cc254ba4716ae3c76dad4a196021c85c38652c150c8ad},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41225624. Agents can read the archived copy with the MCP tool read_document.